GSK Spends $10.6 Billion on Lung Cancer Drugs for Patients Who Run Out of Options

GSK is buying Nuvalent for $10.6 billion to gain experimental drugs that treat lung cancer patients whose tumours have become resistant to existing medicines. The bet hinges on whether Nuvalent's lead drug, zidesamtinib, wins regulatory approval—the moment that will determine if the price was justified.